| NCT ID | NCT04681690 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Association of Urologic Oncology (AUO) |
| Condition | Kidney Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2020-12-15 |
| Primary Completion | 2026-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2020-12-15 with a primary completion date of 2026-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The G-NeSS Registry prospectively collects data on clinical and outcome variables from patients undergoing partial nephrectomy for renal masses. Analyses of data aims at identifying key factors determining the quality of surgical care in this patient population.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Written informed consent * Localized renal parenchymal mass amenable to nephron-sparing surgery * Adequate imaging of the abdomen (CT or MR with contrast) Exclusion Criteria: * Patient with (or suspected to have) urothelial cancer of the kidney * Prior nephron-sparing surgery on ipsilateral kidney * metastasized renal cell carcinoma
Contact & Investigator
Nina Harke, Dr.
STUDY CHAIR
MHH
Frequently Asked Questions
Who can join the NCT04681690 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Kidney Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04681690 currently recruiting?
Yes, NCT04681690 is actively recruiting participants. Contact the research team at harke.nina@mh-hannover.de for enrollment information.
Where is the NCT04681690 trial being conducted?
This trial is being conducted at Hof, Germany, Hanover, Germany, Berlin, Germany, Berlin, Germany and 1 additional location.
Who is sponsoring the NCT04681690 clinical trial?
NCT04681690 is sponsored by Association of Urologic Oncology (AUO). The principal investigator is Nina Harke, Dr. at MHH. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.